15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering Cellectis SA, 3 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets are tightly clustered, $8.00 to $9.00, so the covering firms are broadly aligned. The average target of $8.67 sits 202% above the current $2.87. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.22 next quarter toward $-0.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to Cellectis SA.
As of Jul, 3 of 3 firms rate CLLS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CLLS EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.26 – $-0.17 · 6 analysts · -2348% YoY
Next period, 6 analysts expect Cellectis SA to earn $-0.22 a share (range $-0.26 – $-0.17), versus $0.01 a year earlier. Full-year consensus is $-0.89, growing to $-0.89 the year after.
REVENUE · NEXT QUARTER
$13.0M
Range $6.4M – $16.6M · 6 analysts · -60% YoY
Revenue is expected to reach $13.0M (range $6.4M – $16.6M), -59.6% year-over-year. Full-year consensus is $50.3M, rising to $57.9M next year.
Top analysts covering Cellectis SA
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CLLS.
#1
Gena Wang
Barclays
Buy
$8.00+178.7% to target
Coverage
—
+ Follow
#2
LS
Lukas Shumway
Barclays
Buy
$9.00+213.6% to target
Coverage
—
+ Follow
#3
ST
Silvan Turkcan
Citizens
Buy
$8.00+178.7% to target
Coverage
—
+ Follow
#4
WM
William Maughan
Clear Street
Buy
$9.00+213.6% to target
Coverage
—
+ Follow
#5
Yanan Zhu
Wells Fargo
Hold
$4.00+39.4% to target
Coverage
—
+ Follow
CLLS stock forecast FAQ
What is CLLS's average 12-month price target?+
The 3 analysts with a live target average $8.67 for Cellectis SA over the next 12 months, ranging from a $9.00 high to a $8.00 low.
Is CLLS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 3 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CLLS?+
The Street-high target is $9.00 (Barclays), and the Street-low is $8.00 (Citizens). The average of all 3 active targets is $8.67.
How many Wall Street analysts cover CLLS?+
3 analysts have an active rating on Cellectis SA, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering CLLS?+
Among analysts who currently cover CLLS, Gena Wang of Barclays has the strongest overall Quantellect track record. Their current call is Buy with a $8.00 target.
What is Cellectis SA's projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.26 – $-0.17) across 6 analysts. Full-year EPS is projected at $-0.89, rising to $-0.89 the following year.
How much revenue is Cellectis SA expected to report next quarter?+
Consensus revenue is $13.0M (range $6.4M – $16.6M). Full-year revenue is projected at $50.3M, growing to $57.9M next year.
Have analysts been upgrading or downgrading CLLS lately?+
As of Jul, 3 of 3 firms rate CLLS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CLLS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
